In one more major development, Indian government has given due extension to small and medium pharma companies to comply with new Schedule M (GMP) rules. Previously, firms were required to modify their factories by 2024 but currently, the new deadline is December 2025.
📋 What is Schedule M?
Schedule M is a rule under the Drugs and Cosmetics Act that deals with Good Manufacturing Practices (GMP). It tells companies how to keep their factories clean, safe, and suitable for making medicines. It also ensures that medicines are made with proper quality control and hygiene.
🏭 What This Extension Means
This extension is a major relief for many small pharma companies that were struggling to upgrade their facilities. Setting up a GMP-compliant factory takes time and money. Now, with more time, they can:
- Improve their manufacturing units slowly
- Avoid penalties or shutdowns
- Focus on quality without pressure
This move will help many pharma contract manufacturing companies who work for other pharma brands. These companies now have enough time to meet international standards like WHO-GMP and compete in both Indian and global markets.
🤝 Benefits for Monopoly Medicine Distributors
If you are planning to take a pharma franchise from a monopoly medicine company in India, this is a great time. You will be working with companies that are improving their quality and reputation. This gives you a stronger brand image and better trust among doctors and customers.
📌 Conclusion
The government has supported the small and medium pharmaceutical companies in India by giving an extension in the deadline of GMP. This will make it easier to have more businesses achieving the international standard of quality without closing down. It also increases the confidence in the quest of India to be a leader in pharma manufacturing across the globe.